Pulmonary arterial hypertension: A review in pharmacotherapy

Bhaumik B. Patel, Ying Feng, Angela Cheng-Lai

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is a progressive disease that remains incurable. The past 2 decades have witnessed many advances in PAH-directed therapies. More recently, 3 new oral agents have become available in the United States within the past 2 years. Treprostinil is now available in extended-release oral tablets. Macitentan is the third endothelin receptor antagonist approved for use, demonstrating benefits on morbidity and mortality among patients with PAH in an event-driven study. Riociguat is the first soluble guanylate cyclase stimulator that has been approved for use in the United States. This article reviews the clinical efficacy and safety of these 3 agents and the roles they play in the management of PAH. Additionally, we review the limitations of using surrogate markers such as change in 6-minute walk distance to assess disease progression.

Original languageEnglish (US)
Pages (from-to)33-51
Number of pages19
JournalCardiology in Review
Volume23
Issue number1
DOIs
StatePublished - Dec 14 2015

Fingerprint

Pulmonary Hypertension
Drug Therapy
Tablets
Disease Progression
Biomarkers
Morbidity
Safety
Mortality
Therapeutics

Keywords

  • Macitentan
  • Oral treprostinil
  • Riociguat
  • Six-minute walk distance

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Pulmonary arterial hypertension : A review in pharmacotherapy. / Patel, Bhaumik B.; Feng, Ying; Cheng-Lai, Angela.

In: Cardiology in Review, Vol. 23, No. 1, 14.12.2015, p. 33-51.

Research output: Contribution to journalArticle

Patel, Bhaumik B. ; Feng, Ying ; Cheng-Lai, Angela. / Pulmonary arterial hypertension : A review in pharmacotherapy. In: Cardiology in Review. 2015 ; Vol. 23, No. 1. pp. 33-51.
@article{83e38fda79af4d5a8bb47be8f8560cc5,
title = "Pulmonary arterial hypertension: A review in pharmacotherapy",
abstract = "Pulmonary arterial hypertension (PAH) is a progressive disease that remains incurable. The past 2 decades have witnessed many advances in PAH-directed therapies. More recently, 3 new oral agents have become available in the United States within the past 2 years. Treprostinil is now available in extended-release oral tablets. Macitentan is the third endothelin receptor antagonist approved for use, demonstrating benefits on morbidity and mortality among patients with PAH in an event-driven study. Riociguat is the first soluble guanylate cyclase stimulator that has been approved for use in the United States. This article reviews the clinical efficacy and safety of these 3 agents and the roles they play in the management of PAH. Additionally, we review the limitations of using surrogate markers such as change in 6-minute walk distance to assess disease progression.",
keywords = "Macitentan, Oral treprostinil, Riociguat, Six-minute walk distance",
author = "Patel, {Bhaumik B.} and Ying Feng and Angela Cheng-Lai",
year = "2015",
month = "12",
day = "14",
doi = "10.1097/CRD.0000000000000042",
language = "English (US)",
volume = "23",
pages = "33--51",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Pulmonary arterial hypertension

T2 - A review in pharmacotherapy

AU - Patel, Bhaumik B.

AU - Feng, Ying

AU - Cheng-Lai, Angela

PY - 2015/12/14

Y1 - 2015/12/14

N2 - Pulmonary arterial hypertension (PAH) is a progressive disease that remains incurable. The past 2 decades have witnessed many advances in PAH-directed therapies. More recently, 3 new oral agents have become available in the United States within the past 2 years. Treprostinil is now available in extended-release oral tablets. Macitentan is the third endothelin receptor antagonist approved for use, demonstrating benefits on morbidity and mortality among patients with PAH in an event-driven study. Riociguat is the first soluble guanylate cyclase stimulator that has been approved for use in the United States. This article reviews the clinical efficacy and safety of these 3 agents and the roles they play in the management of PAH. Additionally, we review the limitations of using surrogate markers such as change in 6-minute walk distance to assess disease progression.

AB - Pulmonary arterial hypertension (PAH) is a progressive disease that remains incurable. The past 2 decades have witnessed many advances in PAH-directed therapies. More recently, 3 new oral agents have become available in the United States within the past 2 years. Treprostinil is now available in extended-release oral tablets. Macitentan is the third endothelin receptor antagonist approved for use, demonstrating benefits on morbidity and mortality among patients with PAH in an event-driven study. Riociguat is the first soluble guanylate cyclase stimulator that has been approved for use in the United States. This article reviews the clinical efficacy and safety of these 3 agents and the roles they play in the management of PAH. Additionally, we review the limitations of using surrogate markers such as change in 6-minute walk distance to assess disease progression.

KW - Macitentan

KW - Oral treprostinil

KW - Riociguat

KW - Six-minute walk distance

UR - http://www.scopus.com/inward/record.url?scp=84918555739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918555739&partnerID=8YFLogxK

U2 - 10.1097/CRD.0000000000000042

DO - 10.1097/CRD.0000000000000042

M3 - Article

C2 - 25275717

AN - SCOPUS:84918555739

VL - 23

SP - 33

EP - 51

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 1

ER -